Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, announces participation in two major healthcare conferences. At Citi's 2024 Global Healthcare Conference in Miami, President and CEO Bo Cumbo will join a panel on Neuromuscular Disorders on December 4, 2024, at 1:00 p.m. ET. The following day at the Piper Sandler 36th Annual Healthcare Conference in New York, Cumbo and Chief Medical Officer Gabriel Brooks will participate in a fireside chat at 9:30 a.m. ET. Both events will be webcast live and available for replay on the company's website for 30 days.
Solid Biosciences (Nasdaq: SLDB), un'azienda di medicina genetica di precisione, annuncia la partecipazione a due importanti conferenze nel settore sanitario. Al Citi's 2024 Global Healthcare Conference di Miami, il Presidente e CEO Bo Cumbo parteciper脿 a un panel sulle Malattie Neuromuscolari il 4 dicembre 2024, alle 13:00 ET. Il giorno successivo, al Piper Sandler 36th Annual Healthcare Conference di New York, Cumbo e il Direttore Medico Gabriel Brooks parteciperanno a una chiacchierata informale alle 9:30 ET. Entrambi gli eventi saranno trasmessi in diretta in streaming e disponibili per la visione on-demand sul sito web dell'azienda per 30 giorni.
Solid Biosciences (Nasdaq: SLDB), una empresa de medicamentos gen茅ticos de precisi贸n, anuncia su participaci贸n en dos importantes conferencias de salud. En el Citi's 2024 Global Healthcare Conference en Miami, el Presidente y CEO Bo Cumbo se unir谩 a un panel sobre Trastornos Neuromusculares el 4 de diciembre de 2024, a la 1:00 p.m. ET. Al d铆a siguiente, en el Piper Sandler 36th Annual Healthcare Conference en Nueva York, Cumbo y el Director M茅dico Gabriel Brooks participar谩n en un chat informal a las 9:30 a.m. ET. Ambos eventos se transmitir谩n en vivo y estar谩n disponibles para su reproducci贸n en el sitio web de la empresa durante 30 d铆as.
Solid Biosciences (Nasdaq: SLDB), 鞝曤皜 鞙犾爠 鞚橃暯頀� 須岇偓臧� 霊� 臧滌潣 欤检殧 鞚橂 須岇潣鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. Citi's 2024 Global Healthcare Conference臧� 鞐措Μ電� 毵堨澊鞎犽鞐愳劀, 雽�韱惦牴鞚挫瀽 CEO鞚� Bo Cumbo電� 2024雲� 12鞗� 4鞚� 鞓ろ泟 1鞁�(ET) 鞁犼步攴检湣 歆堩櫂鞐� 雽�頃� 韺剱鞐� 彀胳劃頃� 瓴冹瀰雼堧嫟. 雼れ潓 雮�, 雺挫殨鞐愳劀 鞐措Μ電� Piper Sandler 36th Annual Healthcare Conference鞐愳劀 Cumbo鞕� 斓滉碃 鞚橂 毂呾瀯鞛� Gabriel Brooks電� 鞓れ爠 9鞁� 30攵�(ET) 頇旍儊 毂勴寘鞐� 彀胳棳頃� 瓴冹瀰雼堧嫟. 霊� 頄夓偓 氇憪 靸濎瓿勲悩氅�, 須岇偓 鞗轨偓鞚错姼鞐愳劀 30鞚� 霃欖晥 雼れ嫓 氤� 靾� 鞛堨姷雼堧嫟.
Solid Biosciences (Nasdaq: SLDB), une entreprise de m茅dicaments g茅n茅tiques de pr茅cision, annonce sa participation 脿 deux grandes conf茅rences de sant茅. Lors de Citi's 2024 Global Healthcare Conference 脿 Miami, le Pr茅sident et CEO Bo Cumbo participera 脿 un panel sur les troubles neuromusculaires le 4 d茅cembre 2024 脿 13h00 ET. Le jour suivant, lors de la Piper Sandler 36th Annual Healthcare Conference 脿 New York, Cumbo et le Directeur M茅dical Gabriel Brooks participeront 脿 une discussion informelle 脿 9h30 ET. Les deux 茅v茅nements seront diffus茅s en direct et disponibles en replay sur le site web de l'entreprise pendant 30 jours.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen f眉r pr盲zise genetische Medikamente, gibt die Teilnahme an zwei wichtigen Gesundheitskonferenzen bekannt. Auf der Citi's 2024 Global Healthcare Conference in Miami wird Pr盲sident und CEO Bo Cumbo am 4. Dezember 2024 um 13:00 Uhr ET an einem Panel zu neuromuskul盲ren Erkrankungen teilnehmen. Am folgenden Tag werden Cumbo und der Chief Medical Officer Gabriel Brooks um 9:30 Uhr ET an einem Kamingespr盲ch auf der Piper Sandler 36th Annual Healthcare Conference in New York teilnehmen. Beide Veranstaltungen werden live 眉bertragen und sind f眉r 30 Tage auf der Unternehmenswebsite f眉r eine Wiederholung verf眉gbar.
- None.
- None.
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 鈥淐ompany鈥� or 鈥淪olid鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Citi鈥檚 2024 Global Healthcare Conference 鈥� Miami, FL
Bo Cumbo, President and CEO, will participate in a panel discussion titled 鈥淣euromuscular Disorders鈥� on Wednesday, December 4, 2024, at 1:00 p.m. ET.
- Piper Sandler 36th Annual Healthcare Conference 鈥� New York, NY
Mr. Cumbo and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 5, 2024, at 9:30 a.m. ET.
Live webcasts of the Citi panel discussion and Piper Sandler fireside chat will be available on the Events page of the Investors section of the Company website or by聽. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Citi or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
When is Solid Biosciences (SLDB) presenting at Citi's 2024 Global Healthcare Conference?
What events will Solid Biosciences (SLDB) participate in during December 2024?
How long will the webcasts be available for Solid Biosciences' (SLDB) December 2024 conference presentations?
Who will represent Solid Biosciences (SLDB) at the Piper Sandler Healthcare Conference?
